The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.
Monica D. Mead, MD, discusses the evolving use of the BTK inhibitors in the treatment of patients with MCL, the factors for selecting between ibrutinib, zanubrutinib, and acalabrutinib, and unmet needs for patients with MCL
A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged the limitations and current challenges with these data.
KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS AND MANUFACTURING EXPERIENCE AT EBMT 2023 Stockley Park, UK – 19 April 2023 – Kite, a Gilead Company, will support eight data presentations, including updated findings in multiple indications across its portfolio of two CAR T-c.